{"schema_version":"secwatch.filing_event.v1","accession":"0001835268-26-000019","form_type":"8-K","ticker":"CNTB","cik":"0001835268","company_name":"Connect Biopharma Holdings Ltd","filed_at":"2026-05-12T13:02:24+00:00","discovered_at":"2026-05-12T13:03:00.308893+00:00","generated_at":"2026-05-12T13:03:45.164953+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Connect Biopharma reports Q1 net loss $19.4M; Phase 2 studies on track, topline data mid-2026","bullets":["Net loss $19.4M ($0.34 loss per share) vs $10.3M loss ($0.19 per share) in Q1 2025.","Cash $46.0M as of March 31, 2026; expects funding into H2 2027.","Phase 2 Seabreeze STAT asthma/COPD studies continuing after DMC review; topline data expected mid-2026.","Completed $20.2M private placement led by Panacea Venture on March 31, 2026.","R&D expense $15.0M (up from $6.6M) due to rademikibart development; license revenue $0.2M from Simcere agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001835268-26-000019","json":"https://secwatch.observer/filing/0001835268-26-000019.json","markdown":"https://secwatch.observer/filing/0001835268-26-000019.md","text":"https://secwatch.observer/filing/0001835268-26-000019.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/cntb-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T13:03:45.164953+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e1ec4fa4b62e3cc4660dac94512251fea599b55","claim":"Connect Biopharma Holdings Ltd reported the three months ended March 31, 2026 results: revenue $0.2 million, net income $19.4 million, EPS ($0.34) per share.","evidence_excerpt":"its cash and investments will be sufficient to fund operations into the second half of 2027. • License and collaboration revenues for the three months ended March 31, 2026 were $0.2 million related to the upfront license fee under the license agreement with Simcere. There were no license and collaboration revenues for the three months ended March 31, 2025. As a part","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835268/000183526826000019/0001835268-26-000019-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$0.2 million"},{"label":"Net income","value":"$19.4 million"},{"label":"EPS","value":"($0.34) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}